NCT05534594
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer diagnostic Not Available recruiting NCT04759911
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer treatment 2 recruiting NCT00134043
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer treatment 2 completed NCT00068497
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer treatment Not Available completed NCT02592356
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer supportive_care Not Available completed NCT00519896
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer treatment 2 completed NCT00028496
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer treatment 1 completed NCT01709435
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors treatment 1 completed NCT00118248
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer treatment 2 completed NCT00655655
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT02293954
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer diagnostic Not Available active_not_recruiting NCT03892993
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers No drug interventions supportive_care Not Available recruiting NCT01155258
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors treatment 1 completed NCT00004074
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu treatment 1 completed NCT01204476
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma treatment 1 completed NCT02867592
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors treatment 2 active_not_recruiting NCT05796960
European Multicenter Study on Surgical Management of Advanced Thyroid Cancer No drug interventions Not Available Not Available recruiting NCT02088645
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. treatment 1 recruiting NCT03630120
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer treatment 2 terminated NCT02431715
18F-FDOPA PET in Neuroendocrine Tumours No drug interventions Not Available Not Available no_longer_available NCT03647657
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer basic_science 0 completed NCT04970134
Spanish Study for Molecular Characterization of Thyroid Carcinoma No drug interventions Not Available Not Available active_not_recruiting NCT00880503
Collection of Tissue Samples for Study of Multidrug Resistance No drug interventions Not Available Not Available completed NCT03636945
Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma No drug interventions diagnostic Not Available unknown_status NCT04787328
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) No drug interventions treatment 2 recruiting NCT01511393
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) No drug interventions Not Available Not Available enrolling_by_invitation NCT01424878
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients No drug interventions Not Available Not Available completed NCT01373736
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors No drug interventions diagnostic 3 unknown_status NCT02586350
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) treatment 2 / 3 completed NCT01730638
ImmunoTEP for Patients With Medullary Thyroid Carcinoma. diagnostic 1 / 2 completed NCT00923247
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) treatment 1 / 2 terminated NCT06121271
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications treatment 2 not_yet_recruiting NCT01736878
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma treatment 2 withdrawn NCT03246659
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC treatment 1 completed NCT06520319
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma diagnostic 1 recruiting NCT06067594
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. No drug interventions Not Available Not Available completed NCT00514046
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer treatment 1 / 2 completed NCT03072160
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer treatment 2 completed NCT01856920
QUILT-3.006 for Recurrent Medullary Thyroid Cancer treatment 2 completed NCT01788982
Nintedanib(BIBF1120) in Thyroid Cancer treatment 2 completed NCT01660984
Natural History Study of Children and Adults With Medullary Thyroid Cancer No drug interventions Not Available Not Available recruiting NCT02174679
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) Not Available Not Available no_longer_available NCT02363647
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer No drug interventions treatment Not Available terminated NCT02856347
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin No drug interventions diagnostic Not Available completed NCT06292988
Predictive Factors for Medullary Thyroid Cancer Aggressiveness No drug interventions Not Available Not Available not_yet_recruiting NCT01915485
Radiolabeled Molecules for Medullary Thyroid Cancer No drug interventions treatment 4 unknown_status NCT04211337
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer treatment 3 active_not_recruiting NCT05830500
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma treatment 4 recruiting NCT04522570
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma No drug interventions treatment Not Available recruiting NCT01757470
Vandetanib Risk Minimisation Effectiveness No drug interventions Not Available Not Available completed NCT06243965
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma? No drug interventions Not Available Not Available completed NCT06523582
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients No drug interventions Not Available Not Available recruiting NCT04161391
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations No drug interventions treatment 1 / 2 terminated NCT02709889
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors treatment 1 / 2 terminated NCT03899792
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors treatment 1 / 2 recruiting NCT00582712
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer treatment 2 terminated NCT01683110
Expanded Access of Cabozantinib in Medullary Thyroid Cancer Not Available Not Available approved_for_marketing NCT03643055
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer No drug interventions Not Available Not Available unknown_status NCT01298323
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment treatment 3 active_not_recruiting NCT05278364
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor No drug interventions treatment 1 / 2 recruiting NCT01896479
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer treatment 4 active_not_recruiting NCT05675605
A Study of TY-1091 in Patients With Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04204928
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC Not Available Not Available approved_for_marketing NCT03157128
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) treatment 1 / 2 recruiting NCT04760171
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis No drug interventions Not Available Not Available not_yet_recruiting NCT04760288
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). treatment 3 withdrawn NCT03037385
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors treatment 1 / 2 completed NCT01739634
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer treatment 1 / 2 unknown_status NCT02465424
Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients No drug interventions Not Available Not Available completed NCT01625520
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer treatment 2 completed NCT03906331
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation Not Available Not Available available NCT06277180
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC No drug interventions treatment Not Available recruiting NCT03838692
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer treatment 2 withdrawn NCT06141369
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) No drug interventions treatment Not Available recruiting NCT04280081
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation treatment 2 active_not_recruiting NCT01539655
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib basic_science 1 completed NCT06079723
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study No drug interventions Not Available Not Available not_yet_recruiting